Recombinant FcRn Protein: A Key Tool for IgG and Albumin Homeostasis Regulation and Tumor-Targeted Therapy Research

Author: Senior Product Manager of UA Views：12

This article focuses on the molecular characteristics and biological functions of the neonatal Fc receptor (FcRn), systematically elaborating its core role in extending the half-life of IgG and human serum albumin through pH-dependent mechanisms, analyzing the application strategies of FcRn in autoimmune disease treatment, antibody drug half-life extension, and albumin fusion drug development, and exploring the bidirectional association between aberrant FcRn expression and tumor progression in cancer.

Recent Advances
Product Information

Recent Advances

Recombinant FcRn Protein: A Key Tool for Studying IgG and Albumin Homeostasis Regulation and Tumor-Targeted Therapy

Overview: This article focuses on the molecular characteristics and biological functions of the neonatal Fc receptor (FcRn), systematically elaborating on its core role in extending the half-life of IgG and human serum albumin through a pH-dependent mechanism, analyzing its application strategies in autoimmune disease treatment, antibody drug half-life extension, and albumin fusion drug development, and discussing the bidirectional association between aberrant FcRn expression and tumor progression.

I. Molecular Characteristics of FcRn and Its pH-Dependent Binding Mechanism.

The neonatal Fc receptor (FcRn) is the Fc segment receptor for IgG and the receptor for human serum albumin. It can greatly extend the half-life of IgG and human serum albumin through a pH-dependent mechanism, maintaining stable concentrations of IgG and human serum albumin. The binding of FcRn to its ligands is strictly pH-dependent——in the acidic environment of the endosome at approximately pH 6.0, FcRn binds with high affinity to the Fc segment of IgG and human serum albumin; whereas in the neutral environment outside the cell at approximately pH 7.4, the complex rapidly dissociates, releasing the ligand back to the extracellular environment. This exquisite pH switch mechanism enables FcRn to “rescue” IgG and human serum albumin from the degradation pathway within cellular endosomes and recycle them back to the cell surface for release, thereby significantly extending the circulatory half-life of both ligands. Structurally, FcRn is a heterodimer composed of an α chain homologous to the heavy chain of MHC class I molecules and β2-microglobulin.

II. Drug Development Strategies Targeting FcRn.

Drug development targeting FcRn mainly has three directions. First, extending half-life. Clinical therapeutic monoclonal antibodies are all IgG. By engineering mutations at the binding sites between IgG and FcRn, the half-life of monoclonal antibody drugs can be greatly increased, reducing drug dosage and thereby reducing side effects. Second, improving targeting. Human serum albumin fusion drugs produced through engineering technology can increase half-life while also improving targeting and reducing systemic toxicity. Third, enhancing IgG clearance. Autoimmune diseases produce excessive antibodies. By blocking the binding of FcRn to IgG, the degradation of IgG by cellular lysosomes can be promoted, alleviating disease symptoms. All of the above therapeutic strategies are based on normal FcRn expression, but aberrant FcRn expression in tumors can also serve as a therapeutic entry point.

III. Altered FcRn Expression and Metabolic Reprogramming During Tumor Development.

Hypoproteinemia, which is very common in cancer patients, is associated with excessive consumption of human serum albumin. Tumor cell proliferation rate increases, metabolism correspondingly increases, and the decomposition of human serum albumin is an important source of amino acids required for tumor cell metabolism. Studies have shown that catabolism of human serum albumin is the direct cause of hypoproteinemia. In a mouse model of pancreatic ductal adenocarcinoma, albumin peptide concentration in the pancreas was significantly elevated, suggesting that albumin is extensively decomposed and utilized in the tumor microenvironment.

Moreover, in various human tumors, FcRn exhibits low-level expression, and intracellular human serum albumin exhibits high-level expression. Mice transplanted with tumors lacking FcRn expression showed decreased serum albumin levels, accompanied by increased tumor volume. These studies indicate that during tumor development, FcRn expression decreases, the recycling rate of human serum albumin decreases, and lysosomal decomposition of human serum albumin is enhanced, promoting tumor growth. Low FcRn expression leads to the inability of albumin to be effectively recycled, turning it instead into a source of amino acids required for tumor cell metabolism, thereby supporting rapid tumor proliferation.

IV. Application of FcRn in Prodrug Design and Tumor-Targeted Therapy.

Tumor treatment generally has two directions: killing tumors and enhancing immune cell function. Prodrug technology is the therapeutic approach that should be considered most. By fusing with human serum albumin, drugs can passively target tumor cells, not only enabling targeted release but also greatly reducing systemic toxicity. The low expression of FcRn in tumors is precisely a favorable factor for prodrugs, further amplifying the advantages of prodrugs——low FcRn expression leads to reduced human serum albumin recycling, causing more albumin fusion drugs to be taken up and decomposed by tumor cells, thereby releasing active drugs locally within the tumor.

However, some studies have also observed upregulated FcRn expression in human tumors, which also has a role in promoting tumor growth. This polarization of FcRn expression may differ depending on the degree of tumor progression. In the case of high FcRn expression, engineered FcRn high-binding human serum albumin mutant fusion or monoclonal antibody mutant drugs can become excellent targeted therapeutic approaches. Therefore, in tumor treatment, evaluating the FcRn expression level of tumor cells and formulating corresponding therapeutic strategies can be a therapeutic approach worth considering.

V. Conclusion.

In FcRn-related basic research and drug development, high-quality recombinant FcRn protein is a core tool for dissecting its pH-dependent binding mechanism and evaluating the binding activity of targeted drugs. In response to the needs of FcRn functional research and drug screening, Ubei provides FcRn His Tag Protein, Human. This product is suitable for applications including pH-dependent binding activity analysis of FcRn with IgG Fc segment and human serum albumin, in vitro screening and evaluation of FcRn-targeted antibody drugs, research on FcRn-mediated IgG and albumin recycling mechanisms, and development of FcRn-related tumor-targeted therapeutic strategies.

As a core receptor for the homeostatic regulation of IgG and human serum albumin, FcRn, with its pH-dependent binding mechanism and unique function of extending ligand half-life, has become a key target in the fields of antibody drug engineering, albumin fusion drug development, and autoimmune disease treatment. Its association between downregulated expression in tumors and tumor metabolic reprogramming and hypoproteinemia, as well as its relationship between upregulated expression in some tumors and tumor progression, reveal the complex regulatory network of FcRn in the tumor microenvironment. FcRn His Tag Protein, Human provides reliable tool support for in-depth analysis of the FcRn signaling network and related drug development, and will continue to drive innovative exploration in the fields of antibody engineering and tumor-targeted therapy.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next